Winterhoff Boris, Kommoss Stefan, Heitz Florian, Konecny Gottfried E, Dowdy Sean C, Mullany Sally A, Park-Simon Tjoung-Won, Baumann Klaus, Hilpert Felix, Brucker Sara, du Bois Andreas, Schröder Willibald, Burges Alexander, Shen Steven, Wang Jinhua, Tourani Roshan, Ma Sisi, Pfisterer Jacobus, Aliferis Constantin F
Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, USA.
Institute for Health Informatics, University of Minnesota, MN, USA.
AMIA Annu Symp Proc. 2018 Dec 5;2018:1093-1102. eCollection 2018.
We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.
我们报告了在开发针对卵巢癌个体化使用VEGF-A靶向药物贝伐单抗的精准测试方面的最新进展。我们讨论了发现模型阶段（即过去的可行性建模以及向生产测试转换之前）。主要结果：（a）信息学建模在支持推动临床和卫生经济需求方面发挥着关键作用。（b）新型计算模型支持创建具有足够预测性的精准测试，在10年内可将医疗系统成本降低多达300亿美元，并使贝伐单抗的使用变得可承受，同时不影响寿命长度或生活质量。
